 | Up a level |
Klose, H., Gall, H., Ghofrani, H., Gruenig, E., Humbert, M., Simonneau, G., Halank, M., Langleben, D., Snijder, R. J., Escribano, P., Mielniczuk, L. M., Lange, T., Vachiery, J., Wirtz, H., Helmersen, D. S., Tsangaris, I., Barbera, J. A., Pepke-Zaba, J., Boonstra, A., Rosenkranz, S., Ulrich, S., Mascherbauer, R., Delcroix, M., Jansa, P., Gomez Sanchez, M. A., Klotsche, J., Meier, C., Pittrow, D. and Hoeper, M. M. (2018). Riociguat for the Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Safety Update from the EXPERT Registry. Am. J. Respir. Crit. Care Med., 197. NEW YORK: AMER THORACIC SOC. ISSN 1535-4970
Lang, I., McLaughlin, V., Barbera, J. A., Gomez-Sanchez, M. A., Hoeper, M. M., Jansa, P., Speich, R., Rosenkranz, S., Meier, C., Mueller, K., Nikkho, S., D'Armini, A. M. and Pepke-Zaba, J. (2015). Early Access Study (eas) Of Riociguat In Patients With Chronic Thromboembolic Pulmonary Hypertension (cteph): Baseline Characteristics And Comparison With Registry Data. Am. J. Respir. Crit. Care Med., 191. NEW YORK: AMER THORACIC SOC. ISSN 1535-4970